Plosker, Greg L.; Figgitt, David P. - In: PharmacoEconomics 22 (2004) 6, pp. 389-411
Repaglinide (Prandin(R), NovoNorm(R), GlucoNorm(R)), an oral insulin secretagogue, was the first meglitinide analogue to become available for use in patients with type 2 diabetes mellitus. The drug lowers postprandial glucose excursions by targeting early-phase insulin release, an effect thought...